> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Voucher Awarded to Neurocrine Biosciences
- URL: https://www.fdaweb.com/priority-voucher-awarded-to-neurocrine-biosciences/
- Published: 2025-01-09T12:00:00.000Z
- Updated: 2026-09-14T14:50:34.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5158460

*Federal Register* notice: The FDA is announcing it has issued a priority review voucher to Neurocrine Biosciences because its 12/13 NDA approval for Crenessity (crinecerfont) was a qualifying action. The drug was approved to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients four years of age and older with classic congenital adrenal hyperplasia. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2025-01-10/pdf/2025-00340.pdf?ref=fdaweb.com).